Probable Labetalol-Induced HepatotoxicitySt. John's University College of Pharmacy & Allied Health Professions, Ambulatory Pharmacy Faculty, Beth Israel Residency in Urban Family Practice-Institute for Urban Family Health, 8000 Utopia Parkway, St. Albert's Hall Room 114, Queens, NY 11439, ginzburr{at}stjohns.edu
Beth Israel Residency in Urban Family Practice-Institute for Urban Family Health, New York, New York
Beth Israel Residency in Urban Family Practice-Institute for Family Health, Jamaica, New York, New York This article reports a case of probable hepatotoxicity induced by therapeutic doses of labetalol. A 34-year-old postpartum woman was started on labetalol during a preeclamptic episode in the hospital. During the patient's 4-week postpartum office visit, she reported having dark urine for the previous 2 weeks. A liver function test showed substantial enzyme elevation, which improved after discontinuation of labetalol therapy. Labetalol-induced hepatotoxicity, although uncommon, can occur. Published data report this occurrence only in middle-aged or older patients. This appears to be the first case report of postpartum labetalol-induced hepatotoxicity. Hepatotoxicity may occur as a result of labetalol therapy. More judicious monitoring in patients on labetalol therapy may be warranted to prevent serious outcomes.
Key Words: Labetalol hepatotoxicity postpartum.
Journal of Pharmacy Practice, Vol. 20, No. 3,
283-287 (2007) |
||||